Press Releases

Date	Title	Company
10-Jan-2022	Halo Biosciences Participating in BIO @ JPM and BIOTECH SHOWCASE™ During J.P. Morgan Week 2022	Newswire
10-Jan-2022	QUANTA Dialysis Technologies Appoints Meghan Fitzgerald and Leslie Norwalk to Board of Directors	Businesswire
10-Jan-2022	Sole Source Capital Portfolio Company Peak Technologies Acquires Avalon Integration	Businesswire
10-Jan-2022	ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer	Businesswire
10-Jan-2022	Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection	Businesswire
10-Jan-2022	Bluestar Genomics Appoints David Mullarkey Chief Executive Officer	Businesswire
10-Jan-2022	H3 Biomedicine Welcomes Dr. Richard Woodman to its Board of Directors	Businesswire
10-Jan-2022	Vaxiion Therapeutics Announces Clearance of IND Application for the Intralesional Administration of VAX014 to Subjects with Treatment Refractory Solid Tumors	Businesswire
10-Jan-2022	ANJAC Health & Beauty joins forces with Canadian company APOLLO to expand its North American presence	Businesswire
10-Jan-2022	Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects	Businesswire
10-Jan-2022	Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR	Businesswire
10-Jan-2022	Affini-T Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference	Businesswire
10-Jan-2022	Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022	Businesswire
10-Jan-2022	Sesen Bio Further Enhances Team with Key Hires	Businesswire
10-Jan-2022	ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors	Businesswire
10-Jan-2022	Tenaya Therapeutics Provides 2022 Business Updates	Businesswire
10-Jan-2022	JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada	Businesswire
10-Jan-2022	Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones	Businesswire
10-Jan-2022	DEFENCE THERAPEUTICS ACHIEVES A MAJOR MILESTONE AND BEGINS IND-ENABLING TESTING OF ITS ACCUTOX LEAD COMPOUND AGAINST BREAST CANCER	Defence Therapeutics Inc.
10-Jan-2022	Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results	Businesswire